Skip to main content
Ir a la página de inicio de la Comisión Europea (se abrirá en una nueva ventana)
español es
CORDIS - Resultados de investigaciones de la UE
CORDIS
Contenido archivado el 2024-05-27

Transglutaminase in disease: a novel therapeutic target?

Objetivo

TRANSPATH is a multisectorial Network designed to facilitate the exchange of knowledge and technology between 7 leading European research teams and 3 SME partners and 2 associate SME Partners involved in basic and applied research into transglutaminase (TG) related human diseases. Its ambitions are to accelerate the development of new strategies for the treatment and diagnosis of human diseases related to transglutaminases, including metastatic cancer, neurodegeneration and celiac disease. The subject is highly relevant as deregulation of tissue transglutaminase activity is observed in a number of human diseases while the exact mechanisms are still largely unknown. The project targets this unmet clinical need. The main objectives are :1) to establish the molecular nature of the role of transglutaminases in the pathogenesis of diseases which are known to involve these multifunctional enzymes with a view to developing novel specific inhibitors and new therapeutic approaches which will have a major impact on their treatment ;2) provide an extensive cross sectorial scientific and supporting training network that will increase the capabilities of highly skilled researchers for the European biotechnology industry and academia.

Ámbito científico (EuroSciVoc)

Programa(s)

Tema(s)

Convocatoria de propuestas

FP7-PEOPLE-2011-ITN
Consulte otros proyectos de esta convocatoria

Régimen de financiación

MC-ITN - Networks for Initial Training (ITN)

Coordinador

ASTON UNIVERSITY
Aportación de la UE
€ 795 367,01
Coste total
Sin datos

Participantes (10)